🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06608134
Recruiting Phase EARLY_PHASE1

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis

NCT06608134 · tracked via the Priya Life Science USA tracker
Sponsor
R3 Medical Research
Phase
Phase EARLY_PHASE1
Started
2024-10-01
Last updated
2024-09-23

Condition(s) studied

Osteoarthritis, Knee

Investigational drug(s) / intervention(s)

Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection

Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection: Direct injection of biologic into the knee joint.

Study summary

This is a Pilot Study which is randomized, prospective, open label, dose escalation, non-controlled evaluating safety and feasibility of intra-articular Wharton's Jelly (WJ) allograft will be evaluated in patients suffering with knee osteoarthritis. The participants will be randomized to one of three dosing treatment arms that will consist of one intra-articular knee injection containing either low dose, medium dose or high dose WJ allograft tissue.

Eligibility

Sex
ALL
Min age
30 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Be over age 30 * Diagnosed with Grade II or III OA on the KL scale (in one knee). * Body Mass Index (BMI) \<50Kg/m2 * Pain score of 4 or more on the Numeric Pain Rating Scale (NPRS) * Female patients must be abstinent, surgically sterilized or postmenopausal * Premenopausal females must have a negative pregnancy test, on contraceptive measures and do not anticipate pregnancy during the duration of the study. * Be willing and capable of giving written informed consent to participate in English. * Be willing and capable of complying with study-related requirements, procedures and visits in English. Exclusion Criteria: * Have taken any pain medication including nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to study injection date. * Use anticoagulants have a substance abuse history and fail to agree not to take any knee-symptom modifying drugs during the course of the study without discussing and reporting the use to the site principal investigator and study team. * Have had an intra-articular injection of any drug including viscosupplementation in the index knee in the past 6 months. * Have had surgery on the index knee with the past 6 months. * Had a traumatic injury to the index knee with the past 3 months. * Planned elective surgery during the course of the study. * A history of organ or hematologic transplantation, rheumatoid arthritis, or other autoimmune disorders. * Be on immunosuppressive medications. * Have a diagnosis of carcinoma with the past 2 years. * Have a knee infection or have used antibiotics for knee infection within the past 3 months. * Have participated in any other clinical trial or treatment (not just for the knee, but for any reason) with any investigational product within the past 30 days prior to inclusion of study. * Female patients who are breast feeding or are pregnant or desire to become pregnant during the course of the study. * Contraindications to radiographic or MRI imaging. * Serious neurological, psychological or psychiatric disorders. * Injury or disability claims under current litigation or pending or approved workers compensation claims. * Have a known drug allergy to amphotericin-B, ciprofloxacin, gentamycin, penicillin, or streptomycin.

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
R3 Anti Aging Scottsdale Scottsdale Arizona Recruiting
R3 Anti Aging Beverly Hills Beverly Hills California Recruiting
Optimal Medical Group Fresno California Recruiting
Scheer Medical Wellness New York New York Recruiting
Dr. Duc (Steve) Le, MD Cleveland Texas Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06608134 on ClinicalTrials.gov ↗ ← All trials in the USA